Updated:
Chr. Hansen A/S
Chr. Hansen A/S began as a small laboratory in Copenhagen, Denmark in 1874, co-founded by the brothers Maurice and Christian D.A. Hansen.
Chr. Hansen A/S
Chr. Hansen A/S began as a small laboratory in Copenhagen, Denmark in 1874, co-founded by the brothers Maurice and Christian D.A. Hansen. The firm developed and produced yeast for baking and later expanded into microbial cultures for dairy and food preservation. The Hansen family built and operated the business as a private company for over a century, eventually listing it on the Copenhagen Stock Exchange in 1975. The wealth generated by the Hansen family from Chr. Hansen's operations was partially reinvested into the firm and distributed among family branches over generations. The company's strategy centered on the development and production of natural food cultures, probiotics, enzymes, and natural colors for the global food, beverage, and dietary supplement industries. Chr. Hansen operated across three core business segments: Food Cultures & Enzymes, Health & Nutrition (including human and animal probiotics), and Natural Colors. The company maintained a strong footprint in Europe, the Americas, and Asia, with production plants in Denmark, the United States, France, and Brazil. The firm supplied cultures used in dairy production worldwide, serving major food and beverage companies as customers. The company's technologies focused on fermentation biology and microbial science. Chr. Hansen employed approximately 4,000 professionals globally before its acquisition. The firm maintained offices in more than 20 countries and operated multiple R&D centers. The company's philanthropic arm, the Chr. Hansen Foundation, was established in 1983 and funded scientific research in food science and microbiology. In December 2022, Novozymes completed its acquisition of Chr. Hansen to create Novonesis, a combined microbial solutions firm valued at roughly $11.9B (per Reuters, December 2022). The Hansen family, through holding vehicles and charitable foundations, maintained a stake in the merged entity. The structural differentiator for the Hansen wealth is its passage from a family-controlled industrial biotechnology firm to a publicly traded entity acquired by an industry peer. Unlike single-family offices that maintain concentrated ownership of a private business, the Hansen family's wealth is now largely dispersed through public markets and philanthropic structures. This trajectory reflects a European pattern of dynastic industrial families transitioning to institutional ownership.
General information
Firm type
Asset Manager
Year founded
1874
AUM
Undisclosed
Location
Region
Europe
Country
Denmark
City
Hoersholm
Corporate office
Hoersholm, Denmark
Additional offices
Milwaukee, WI, United States · Paris, France · Mumbai, India · São Paulo, Brazil · Shanghai, China
Principals
Maurice Hansen
Co-Founder
Christian D.A. Hansen
Co-Founder
Sector focus
Frequently asked questions
Who founded Chr. Hansen A/S and what was the wealth origin?
Chr. Hansen was founded in 1874 by the brothers Maurice and Christian D.A. Hansen as a laboratory in Copenhagen producing yeast and microbial cultures. The Hansen family wealth originated from the development and global sale of food cultures, probiotics, and enzymes used in dairy, dietary supplements, and food preservation. The firm went public in 1975 and was acquired by Novozymes in 2022.
What was Chr. Hansen's investment strategy and how did it deploy capital?
Chr. Hansen invested heavily in R&D for natural fermentation biology, developing and licensing microbial cultures, probiotics, and natural colors. The firm operated as an industrial company rather than a financial investment vehicle, deploying capital into organic growth, acquisitions of complementary biotechnology firms, and building production facilities across Europe, the Americas, and Asia. During its independent existence, it did not operate as a family office managing external capital.
How is the Hansen family wealth managed today following the Novozymes acquisition?
Following the acquisition by Novozymes in 2022, the Hansen family's wealth is largely held through shares in the newly combined Novonesis entity and through the Chr. Hansen Foundation. The family's holding structure is not publicly detailed as a single-family office; instead, wealth is managed primarily through public equities and a philanthropic foundation focused on food science research.
What sectors and industries did Chr. Hansen focus on as an operating company?
Chr. Hansen was a biotechnology company focused on AgriTech, FoodTech, and Health & Nutrition. The firm produced microbial cultures for dairy (cheese, yogurt), probiotics for human and animal health, enzymes for food processing, and natural colors for beverages and confectionery. It served the global food, beverage, and dietary supplement industries.
Does the Hansen family operate a single-family office or investment arm?
There is no publicly documented single-family office managing Hansen family capital separately. The Chr. Hansen Foundation is a charitable arm, and the family's financial interests are represented through the holding structure of the former public company. No external family office investment entity has been identified in public records.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: